Background Injectable cabotegravir (CAB) and rilpivirine (RPV) long-acting (LA) is a new antiretroviral treatment (ART) for HIV-1 infection in virologically suppressed people with HIV (PWH). The study aims to describe outcomes at six months after switch to CAB/RPV and provide a specific subgroup analysis for PWH coming from tenofovir alafenamide (TAF)-containing regimens.
EFFICACY, SAFETY AND METABOLIC CHANGES AT 6- MONTHS AFTER SWITCH TO LONG-ACTING INJECTABLE CAB/RPV: RESULTS FROM AN OBSERVATIONAL PROSPECTIVE MULTICENTER STUDY
GF Pellicanò;
2024-01-01
Abstract
Background Injectable cabotegravir (CAB) and rilpivirine (RPV) long-acting (LA) is a new antiretroviral treatment (ART) for HIV-1 infection in virologically suppressed people with HIV (PWH). The study aims to describe outcomes at six months after switch to CAB/RPV and provide a specific subgroup analysis for PWH coming from tenofovir alafenamide (TAF)-containing regimens.File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
